v3.25.2
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total Stockholder's Equity
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Deferred Compensation
Noncontrolling Interests
Total
Beginning Balance at Oct. 31, 2023 $ 682,493 $ 2 $ 2,199,704 $ (1,515,541) $ (1,672) $ (1,078) $ 1,078 $ 17,955 $ 700,448
Beginning Balance at (in shares) at Oct. 31, 2023   15,020,872              
Common stock issued, non-employee compensation 51   51           51
Common stock issued, non-employee compensation (in shares)   1,480              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (926)   (926)           (926)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   41,173              
Share based compensation 2,876   2,876           2,876
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation 33       33       33
Adjustment for deferred compensation           (51) 51    
Adjustment for deferred compensation (in shares)   (1,480)              
Contributions received for sale of noncontrolling interest               25,122 25,122
Distribution to non-controlling interest               (236) (236)
Net Loss (19,793)     (19,793)       (24,606) (44,399)
Ending Balance at Jan. 31, 2024 663,934 $ 2 2,200,905 (1,535,334) (1,639) (1,129) 1,129 18,235 682,169
Ending Balance at (in shares) at Jan. 31, 2024   15,062,045              
Beginning Balance at Oct. 31, 2023 682,493 $ 2 2,199,704 (1,515,541) (1,672) (1,078) 1,078 17,955 700,448
Beginning Balance at (in shares) at Oct. 31, 2023   15,020,872              
Effect of foreign currency translation                 96
Net Loss                 (117,178)
Ending Balance at Jul. 31, 2024 675,762 $ 2 2,277,470 (1,600,134) (1,576) (1,198) 1,198 9,345 685,107
Ending Balance at (in shares) at Jul. 31, 2024   18,461,340              
Beginning Balance at Jan. 31, 2024 663,934 $ 2 2,200,905 (1,535,334) (1,639) (1,129) 1,129 18,235 682,169
Beginning Balance at (in shares) at Jan. 31, 2024   15,062,045              
Sale of common stock, net of fees 5,893   5,893           5,893
Sale of common stock, net of fees (in shares)   215,457              
Common stock issued, non-employee compensation 47   47           47
Common stock issued, non-employee compensation (in shares)   1,545              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (52)   (52)           (52)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   2,287              
Share based compensation 3,002   3,002           3,002
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (78)       (78)       (78)
Adjustment for deferred compensation           (35) 35    
Adjustment for deferred compensation (in shares)   (1,132)              
Distribution to non-controlling interest               (425) (425)
Net Loss (32,140)     (32,140)       (5,516) (37,656)
Ending Balance at Apr. 30, 2024 639,806 $ 2 2,208,995 (1,567,474) (1,717) (1,164) 1,164 12,294 652,100
Ending Balance at (in shares) at Apr. 30, 2024   15,280,202              
Sale of common stock, net of fees 65,848   65,848           65,848
Sale of common stock, net of fees (in shares)   3,174,005              
Common stock issued, non-employee compensation 47   47           47
Common stock issued, non-employee compensation (in shares)   2,345              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards 30   30           30
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   6,506              
Share based compensation 3,350   3,350           3,350
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation 141       141       141
Adjustment for deferred compensation           (34) 34    
Adjustment for deferred compensation (in shares)   (1,718)              
Distribution to non-controlling interest               (485) (485)
Net Loss (32,660)     (32,660)       (2,464) (35,123)
Ending Balance at Jul. 31, 2024 675,762 $ 2 2,277,470 (1,600,134) (1,576) (1,198) 1,198 9,345 685,107
Ending Balance at (in shares) at Jul. 31, 2024   18,461,340              
Beginning Balance at Oct. 31, 2024 656,922 $ 2 2,300,031 (1,641,550) (1,561) (1,198) 1,198 10,687 $ 667,609
Beginning Balance at (in shares) at Oct. 31, 2024   20,375,932             20,375,932
Sale of common stock, net of fees 5,892   5,892           $ 5,892
Sale of common stock, net of fees (in shares)   690,711              
Common stock issued, non-employee compensation 82   82           82
Common stock issued, non-employee compensation (in shares)   8,335              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (468)   (468)           (468)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   75,834              
Share based compensation 2,142   2,142           2,142
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (232)       (232)       (232)
Adjustment for deferred compensation           (70) 70    
Adjustment for deferred compensation (in shares)   (7,040)              
Contributions received for sale of noncontrolling interest               4,000 4,000
Distribution to non-controlling interest               (600) (600)
Net Loss (28,326)     (28,326)       (4,060) (32,386)
Ending Balance at Jan. 31, 2025 635,212 $ 2 2,306,879 (1,669,876) (1,793) (1,268) 1,268 10,027 645,239
Ending Balance at (in shares) at Jan. 31, 2025   21,143,772              
Beginning Balance at Oct. 31, 2024 656,922 $ 2 2,300,031 (1,641,550) (1,561) (1,198) 1,198 10,687 $ 667,609
Beginning Balance at (in shares) at Oct. 31, 2024   20,375,932             20,375,932
Effect of foreign currency translation                 $ (320)
Net Loss                 (162,031)
Ending Balance at Jul. 31, 2025 556,171 $ 3 2,357,630 (1,799,581) (1,881) (1,360) 1,360 9,049 $ 565,220
Ending Balance at (in shares) at Jul. 31, 2025   29,645,294             29,645,294
Beginning Balance at Jan. 31, 2025 635,212 $ 2 2,306,879 (1,669,876) (1,793) (1,268) 1,268 10,027 $ 645,239
Beginning Balance at (in shares) at Jan. 31, 2025   21,143,772              
Sale of common stock, net of fees 7,665   7,665           7,665
Sale of common stock, net of fees (in shares)   1,626,319              
Common stock issued, non-employee compensation 46   46           46
Common stock issued, non-employee compensation (in shares)   12,013              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (7)   (7)           (7)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   6,102              
Share based compensation 4,824   4,824           4,824
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation 286       286       286
Adjustment for deferred compensation           (46) 46    
Adjustment for deferred compensation (in shares)   (12,013)              
Distribution to non-controlling interest               (565) (565)
Net Loss (38,049)     (38,049)       300 (37,749)
Ending Balance at Apr. 30, 2025 609,177 $ 2 2,318,607 (1,707,925) (1,507) (1,314) 1,314 9,762 618,939
Ending Balance at (in shares) at Apr. 30, 2025   22,776,193              
Sale of common stock, net of fees 38,069 $ 1 38,068           38,069
Sale of common stock, net of fees (in shares)   6,846,992              
Common stock issued, non-employee compensation 46   46           46
Common stock issued, non-employee compensation (in shares)   8,999              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards 18   18           18
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   22,109              
Share based compensation 1,691   1,691           1,691
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (374)       (374)       (374)
Adjustment for deferred compensation           (46) 46    
Adjustment for deferred compensation (in shares)   (8,999)              
Distribution to non-controlling interest               (473) (473)
Net Loss (91,656)     (91,656)       (240) (91,896)
Ending Balance at Jul. 31, 2025 $ 556,171 $ 3 $ 2,357,630 $ (1,799,581) $ (1,881) $ (1,360) $ 1,360 $ 9,049 $ 565,220
Ending Balance at (in shares) at Jul. 31, 2025   29,645,294             29,645,294